PATIENT INFORMATION LEAFLET
QuetiapinaTarbis 50 mg prolonged-release tablets EFG
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
This medication contains a substance called quetiapina. It belongs to a group of medications called antipsychotics. Quetiapina may be used to treat various diseases, such as:
When using this medication to treat major depressive episodes in major depressive disorder, it will be taken in addition to another medication that is being used to treat this disease.
Your doctor may continue prescribing this medication even when you are feeling better.
Do not take this medicine if the above mentioned applies to you. If you are unsure, consult your doctor or pharmacist before takingthismedicine.
Consult your doctor or pharmacist before starting to takethismedicine if:
Inform your doctor immediately if after taking this medicine you experience any of the following:
These disorders may be caused by this type of medicine.
Inform your doctor as soon as possible if you have:
Thoughts of suicide and worsening of depression
If you are depressed, you may sometimes think about harming yourself or committing suicide. This may increase at the beginning of treatment, as all these medicines take time to take effect, usually around two weeks but sometimes longer. These thoughts may also increase if you stop taking your medication abruptly. You may be more likely to think this way if you are a young adult. Information obtained from clinical trials has shown an increased risk of thoughts of suicide and/or suicidal behavior in young adults under 25 years with depression.
If at any time you think about harming yourself or committing suicide, contact your doctor or go to a hospital immediately. It may help to tell a close family member or friend that you are depressed, and ask them to read this leaflet. You may ask them to tell you if they think your depression is getting worse, or if they are concerned about changes in your behavior.
Weight gain
Weight gain has been observed in patients taking quetiapine. You and your doctor should monitor your weight regularly.
Children and adolescents
This medicine should not be used in children and adolescents under 18 years of age.
Taking Quetiapina Tarbis with other medicinesTarbiswith other medicines
Inform your doctor or pharmacist if you are taking or have recently taken or may need to take any other medicine.
Do not takequetiapineif you are using any of the following medicines:
Inform your doctor if you are taking any of the following medicines:
Before stopping any of your medicines, consult your doctor first.
Taking Quetiapina Tarbis with food, drinks, and alcohol
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. Do not take this medicine during pregnancy, unless you have consulted your doctor. Do not use this medicine if you are breastfeeding.
The following symptoms, which may represent withdrawal syndrome, may appear in newborn babies of mothers who have used quetiapine in the last trimester (last three months of pregnancy): tremor, muscle stiffness, and/or weakness, drowsiness, agitation, respiratory problems, and difficulty feeding. If your newborn develops any of these symptoms, you may need to contact your doctor.
Driving and operating machinery
This medicine may cause symptoms such as drowsiness, dizziness, or visual disturbances, and may decrease your reaction time. These effects, as well as the underlying illness, may impair your ability to drive vehicles or operate machinery. Therefore, do not drive, operate machinery, or engage in other activities that require special attention, until your doctor assesses your response to this medicine.
Effect on Drug Detection Tests in Urine
If you are undergoing a urine drug detection test, taking this medicine may produce positive results for methadone or certain antidepressant medicines called tricyclic antidepressants (TCAs) when using certain analysis methods, although you may not be taking methadone or TCAs. If this occurs, a more specific test may be performed.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again. Your doctor will decide your initial dose. The maintenance dose (daily dose) will depend on your disease and needs, but it will normally be between 150 mg and 800 mg.
Liver problems
If you have liver problems, your doctor may change your dose.
Older adults
If you are an older adult, your doctor may change your dose.
Use in children and adolescents
This medication should not be used in children and adolescents under 18 years of age.
If you take more Quetiapina Tarbis than you should
If you take more medication than your doctor prescribed, you may feel drowsy, feel dizzy, and experience abnormal heartbeats. Contact your doctor or the nearest hospital immediately. Bring your Quetiapina tablets with you. You can also call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount taken.
If you forgot to take Quetiapina Tarbis
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, wait until then. Do not take a double dose to make up for the missed tablet.
If you interrupt treatment with Quetiapina Tarbis
If you stop taking this medication abruptly, you may be unable to sleep (insomnia), or you may feel nausea, or you may experience headaches, diarrhea, vomiting, dizziness, or irritability. Your doctor may suggest reducing the dose gradually before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, quetiapinacan cause side effects, although not everyone will experience them.
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1,000 people):
Very rare side effects(may affect up to 1 in 10,000 people):
Not known(the frequency cannot be estimated from the available data):
The class of medications to which quetiapinabelongs may cause heart rhythm problems that can be serious and, in severe cases, fatal.
Some side effects are only observed when a blood test is performed. These include changes in the amount of certain fats (triglycerides and total cholesterol) or blood sugar, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreases in the number of certain types of blood cells, decreases in the number of red blood cells, increases in creatine phosphokinase in the blood (a substance found in muscles), decreases in the amount of sodium in the blood, and increases in the amount of prolactin hormone in the blood. Prolactin increases may, in rare cases, lead to:
Your doctor may ask you to have blood tests from time to time.
Side effects in children and adolescents
The same side effects that may occur in adults may also occur in children and adolescents.
The following side effects have been observed more frequently in children and adolescents or have not been observed in adults:
Very common side effects (may affect more than 1 in 10 people):Increased amount of a hormone called prolactin in the blood. Prolactin increases may, in rare cases, lead to:
Common side effects(may affect up to 1 in 10 people):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use (website:www.notificaRAM.es). By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Thismedicationdoes not require special storage conditions.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Quetiapina Tarbis
Appearance of the product and content of the container
The tablets of this medication are brown in color and have "Q 50" engraved on one side.
The available containers are:
Holder of the marketing authorization
Tarbis Farma, S.L.
Gran Vía Carlos III, 94
08028 Barcelona (Spain)
Responsible for manufacturing
Merckle GmbH
Ludwig-Merckle Strasse 3
D-89143 Blaubeuren-Weiler
Germany
or
Teva UK
Brampton Road, HampdenPark, Eastbourne, East Sussex, BN22 9AG
United Kingdom
Last review date of the leaflet:July 2024
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.